{"id":6013,"date":"2025-03-26T10:30:37","date_gmt":"2025-03-26T01:30:37","guid":{"rendered":"https:\/\/www.infront.kyoto-u.ac.jp\/?page_id=6013"},"modified":"2025-03-26T10:30:37","modified_gmt":"2025-03-26T01:30:37","slug":"labo42","status":"publish","type":"page","link":"https:\/\/www.infront.kyoto-u.ac.jp\/en\/laboratory\/labo42\/","title":{"rendered":"Division of Clinical Basis for ES Cell Research"},"content":{"rendered":"<div id=\"pagehead\">\n<h2>LABORATORY<span>About our laboratory<\/span><\/h2>\n<\/div>\n<div id=\"pankuzu\"><a href=\"..\/..\/\">HOME<\/a> &gt; <a href=\"..\/\">Faculty<\/a> &gt; Division of Clinical Basis for ES Cell Research<\/div>\n<p><main id=\"main\" class=\"laboratory\"><\/p>\n<div class=\"contents\">\n<div class=\"department\">\n<p class=\"field\">Division of Clinical Basis for ES Cell Research<\/p>\n<\/p><\/div>\n<ul class=\"web-list\">\n<li><a href=\"https:\/\/www2.infront.kyoto-u.ac.jp\/es01\/top.htm\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"\/assets\/img\/laboratory\/i_web.svg\" alt=\"Website\"><\/a><\/li>\n<\/ul><\/div>\n<div class=\"message\">\n<h3 class=\"tit\">MESSAGE FROM THE LAB<\/h3>\n<div class=\"contents\">\n<p>In our department, we first established a human ES cell line in Japan, and our research results are being used not only in human ES cells but also in human iPS cells. Regenerative medicine using cells and tissues derived from human ES cells and human iPSC cells (collectively called human pluripotent stem cells (hPSC)) is now at the stage of clinical trials where safety and efficacy have been confirmed worldwide. Our laboratory is developing the basic technology for this, and at the same time, we are establishing human ES cell lines for clinical use.<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<div class=\"photo\"><img decoding=\"async\" src=\"\/assets\/img\/laboratory\/labo42\/photo2025.jpg\" alt=\"Division of Clinical Basis for ES Cell Research\"><\/div>\n<div class=\"member\">\n<div class=\"contents\">\n<div class=\"professer\">\n<div class=\"photo-p\"><img decoding=\"async\" src=\"\/assets\/img\/laboratory\/labo42\/prof.jpg\" alt=\"\"><\/div>\n<div class=\"identity\">\n<p><span class=\"position\">Associate Professor<\/span><span class=\"name\">Eihachiro Kawase<\/span><\/p>\n<\/div>\n<ul class=\"msg-list\">\n<li><a href=\"https:\/\/www2.infront.kyoto-u.ac.jp\/es01\/top.htm\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"\/assets\/img\/laboratory\/i_web.svg\" alt=\"Website\"><\/a><\/li>\n<li><a href=\"m&#97;&#105;&#108;&#116;&#111;&#58;&#107;&#97;&#119;&#97;&#115;&#101;&#56;&#64;&#105;&#110;&#102;&#114;&#111;&#110;&#116;&#46;&#107;&#121;&#111;&#116;&#111;&#45;&#117;&#46;&#97;&#99;&#46;jp\"><img decoding=\"async\" src=\"\/assets\/img\/laboratory\/i_ms.svg\" alt=\"Mail\"><\/a><\/li>\n<\/ul><\/div>\n<div class=\"assistant\">\n<div>\n<p><span class=\"position\">Program-Specific Assistant Professor<\/span><br \/><span class=\"name\">Kei Takada<\/span><\/p>\n<p><a href=\"&#109;&#97;&#105;&#108;&#116;&#111;&#58;&#116;&#97;&#107;&#97;&#100;&#97;&#46;&#107;&#101;&#105;&#46;&#55;&#117;&#64;&#107;&#121;&#111;&#116;&#111;&#45;&#117;&#46;&#97;&#99;&#46;&#106;&#112;\"><img decoding=\"async\" src=\"\/assets\/img\/laboratory\/i_ms.svg\" alt=\"Mail\"><\/a><\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div class=\"research\">\n<h3 class=\"tit\">RESEARCH<\/h3>\n<div class=\"contents\">\n<div class=\"field\">\n<h4><span>Development and implementation of basic research for the establishment and utilization of human ES cell lines for clinical use<\/span><\/h4>\n<p>Regenerative medicine using cells and tissues derived from human ES cells and human iPS cells has attracted worldwide attention. It is currently in the clinical trial stage, where safety and efficacy are confirmed. Our laboratory is engaged in establishing human ES cell lines for clinical use, stock production, and distribution to (clinical) research facilities. At the same time, we are developing the necessary fundamental technologies for this purpose.<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<div class=\"bg-field\">\n<div class=\"field\">\n<h4>Phase contrast photograph of the first human ES cells established in Japan<\/h4>\n<div class=\"with-photo\">\n<p class=\"txt\">As shown in the photo, human ES cells were cultured with support cells called feeder cells in culture media containing animal components, which was unsuitable for clinical use. The development of culture substrates and culture media was essential for the realization of regenerative medicine using human ES cells and human iPS cells.<\/p>\n<p class=\"img\"><img decoding=\"async\" src=\"\/images\/lab_kawase_img1en.jpg\" alt=\"\"><\/p>\n<\/p><\/div>\n<\/p><\/div>\n<div class=\"field\">\n<h4>Development of an efficient human pluripotent stem cell culture method using the LM-E8 Fragment<\/h4>\n<div class=\"with-photo\">\n<p class=\"txt\">Matrigel was conventionally used as a culture substrate for human ES cells and human iPS cells, but it was not suitable for practical use in regenerative medicine. In collaboration with Prof. Sekiguchi of Osaka University, we found that Laminin-511 is appropriate and that its E8 fragment (a) is the minimal constitutive site. Using this LM-E8 fragment, we found that cells grow, survive, and increase more efficiently than Matrigel (b,c). This EM-E8 fragment has been commercialized as iMatrix and is used worldwide.<br \/>Adapted in part from Nature Communication (DOI: 10.1038\/ncomms2231)<\/p>\n<p class=\"img\"><img decoding=\"async\" src=\"\/images\/lab_kawase_img2en.jpg\" alt=\"\"><\/p>\n<\/p><\/div>\n<\/p><\/div>\n<div class=\"field\">\n<div class=\"with-photo\">\n<p class=\"txt\">Photographs of work in the cell processing facility at the institute (Left) and some of the data from the clinical human ES cell line (KthES11) established in this facility (Right).<br \/>Adapted in part from Stem Cell Research (DOI: 10.1016\/j.scr.2020.102020)<\/p>\n<p class=\"img\"><img decoding=\"async\" src=\"\/images\/lab_kawase_img3.jpg\" alt=\"\"><\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<p>  \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n<br \/>\n<\/main><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LABORATORYAbout our laboratory HOME &gt; Faculty &gt; Division of Clinical Basis for ES Cell Research Division of Clinical Basis for ES Cell Research MESSAGE FROM THE LAB In our department, we first established a human ES cell line in Japan, and our research results are being used not only in human ES cells but also [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":131,"menu_order":42,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_locale":"en_US","_original_post":"https:\/\/www.infront.kyoto-u.ac.jp\/?page_id=6011","footnotes":""},"class_list":["post-6013","page","type-page","status-publish","hentry","en-US"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.infront.kyoto-u.ac.jp\/wp-json\/wp\/v2\/pages\/6013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.infront.kyoto-u.ac.jp\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.infront.kyoto-u.ac.jp\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.infront.kyoto-u.ac.jp\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.infront.kyoto-u.ac.jp\/wp-json\/wp\/v2\/comments?post=6013"}],"version-history":[{"count":1,"href":"https:\/\/www.infront.kyoto-u.ac.jp\/wp-json\/wp\/v2\/pages\/6013\/revisions"}],"predecessor-version":[{"id":6014,"href":"https:\/\/www.infront.kyoto-u.ac.jp\/wp-json\/wp\/v2\/pages\/6013\/revisions\/6014"}],"up":[{"embeddable":true,"href":"https:\/\/www.infront.kyoto-u.ac.jp\/wp-json\/wp\/v2\/pages\/131"}],"wp:attachment":[{"href":"https:\/\/www.infront.kyoto-u.ac.jp\/wp-json\/wp\/v2\/media?parent=6013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}